Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein

Circulation

Volumn 107, Issue 23, 2003, Pages 2944-2948

  Bisoendial, Radjesh J ^a   Hovingh, G Kees ^a   Levels, Johannes H M ^a   Lerch, Peter G ^b   Andresen, Irmgard ^b   Hayden, Michael R ^c   Kastelein, John J P ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ZLB Bioplasma AG   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apolipoproteins; Endothelium; Lipoproteins; Nitric oxide

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PHOSPHATIDYLCHOLINE; SEROTONIN; VASODILATOR AGENT;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPOALPHALIPOPROTEINEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD FLOW VELOCITY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FOREARM; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MUTATION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PHOSPHATIDYLCHOLINES; RECOVERY OF FUNCTION; SEROTONIN; TANGIER DISEASE; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0038311032     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000070934.69310.1A     Document Type: Article

References (34)

1. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001;42:545-552.
2. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
3. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor. JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
4. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
5. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol. 2000l;86:11L-14L.
6. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995;75:1196-1201.
7. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-345.
8. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest. 2000;106:1263-1270.
9. van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002;359:37-42.
10. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000;86:1129-1134.
11. Stroes ES, Koomans HA, de Bruin TW, et al. Vascular function in the forearm of hypercholesterolaemic patients of blood pressure and f and on lipid-lowering medication. Lancet. 1995;346:467-471.
12. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens. 2001;19:415-420.
13. Clarkson P, Celermajer DS, Powe AJ, et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 1997;96:3378-3383.
14. Gaenzer H, Neumayr G, Marschang P, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol. 2002;89:431-434.
15. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
16. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
17. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
18. Gokce N, Keaney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567-1572.
19. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996;184:1601-1608.
20. Lerch PG, Fortsch V, Hodler G, et al. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996;71:155-164.
21. Levels JH, Abraham PR, van den EA, et al. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun. 2001;69:2821-2828.
22. Holvoet P, Collen D, Van de WF. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999;281:1718-1721.
23. Brousseau ME, Eberhart GP, Dupuis J, et al. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 2000;41:1125-1135.
24. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586-1593.
25. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001;280:F193-F206.
26. Orso E, Broccardo C, Kaminski WE, et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat Genet. 2000;24:192-196.
27. Fielding PE, Nagao K, Hakamata H, et al. A two-step mechanism for free cholesterol and phospholipid efflux from human vascular cells to apolipoprotein A-1. Biochemistry. 2000;39:14113-14120.
28. Liao H, Langmann T, Schmitz G, et al. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:127-132.
29. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481-1494.
30. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-1508.
31. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278-11283.
32. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-857.
33. Li XA, Titlow WB, Jackson BA, et al. High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem. 2002;277:11058-11063.
34. Sviridov D, Fidge N, Beaumier-Gallon G, et al. Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochem J. 2001;358:79-86.